Cellebrite DI Ltd. SEC filings document its foreign private issuer reporting for an AI-powered digital investigative and intelligence software business. Form 6-K current reports furnish quarterly and annual results releases, GAAP financial tables incorporated by reference into Form S-8 and Form F-3 registration statements, and annual general meeting voting results under the Israeli Companies Law and the company’s articles of association.
The filing record also includes Form 20-F annual reporting, which provides the recurring public-company framework for Cellebrite’s business, financial reporting and ordinary-share governance disclosures.
Cellebrite DI Ltd. (CLBT) Chief Financial Officer David Barter sold 12,134 ordinary shares on October 16, 2026, at a weighted average price of $11.2139 per share. The shares had been granted as restricted stock units on July 7, 2025, and their disposition was associated with tax obligations tied to vesting. Barter directly held 322,085 shares after the sale. No Rule 10b5-1 plan is reported.
Cellebrite DI Ltd. (CLBT) ordinary shares are reported as beneficially owned by Pertento Partners LLP, Pertento Advisors LLC and Eduardo Marques, with each reporting 13,164,696 shares, or 5.2% of the class. Each reports shared voting and dispositive power over 13,164,696 shares and zero sole voting or dispositive power; the repeated amounts describe the same reported position, not three separate holdings to aggregate.
The securities are directly owned by advisory clients of Pertento Partners LLP and Pertento Advisors LLC. Each reporting person disclaims beneficial ownership except to the extent of any pecuniary interest.
Cellebrite DI Ltd. Chief Financial Officer David Barter reported an intention to sell 23,497 ordinary shares on October 16, 2026, with a listed aggregate market value of $267,160.89. The planned sale is under a mandatory, non-discretionary sell-to-cover arrangement solely to satisfy income tax liabilities incurred upon vesting of restricted stock unit awards.
Cellebrite DI Ltd. director Ryusuke Utsumi received an award of 15,190 restricted share units on September 17, 2026. The units are scheduled to vest on September 17, 2027; each represents a contingent right to receive one ordinary share upon settlement. His reported direct holdings following the transaction were 66,586 ordinary shares.
Cellebrite DI Ltd. director Yonatan Domnitz received an award of 15,190 restricted share units on September 17, 2026. The units are scheduled to vest on September 17, 2027, and each represents a contingent right to receive one ordinary share upon settlement. His reported direct holdings following the transaction were 86,586 ordinary shares.
Cellebrite DI Ltd. director Adam Clammer received an award of 15,190 restricted share units (RSUs) on September 17, 2026. The RSUs vest on September 17, 2027, and each represents a contingent right to receive one ordinary share upon settlement. His reported direct holdings after the award were 86,586 ordinary shares.
Reported indirect holdings included 13,861,007 ordinary shares held by TWC Tech Holdings II, LLC, including 1,500,000 shares subject to transfer restrictions pending performance-based vesting conditions, and 375,000 shares each held by Long Term Trust and Joint Revocable Trust. Clammer may be deemed to share beneficial ownership of TWC-held shares as a managing member of its ultimate controlling entity; he disclaims beneficial ownership except to the extent of his pecuniary interest.
Cellebrite DI Ltd. (CLBT) Chief Executive Officer and director Ramji Shiven acquired an award of 38,505 restricted share units on September 24, 2026. Each unit represents a contingent right to receive one ordinary share upon settlement, and the reported direct position following the award was 462,055 ordinary shares. The units vest in installments beginning May 4, 2027; no Rule 10b5-1 plan is reported.
Cellebrite DI Ltd. (CLBT) shareholders approved the re-election of Brandon Van Buren and Ryusuke Utsumi as Class II directors, to serve until the close of the 2029 annual meeting and until their successors are duly elected and qualified. They also approved Chief Executive Officer Shiven Ramji’s compensation package, the company’s compensation policy for officers and directors, and the re-appointment of Kost Forer Gabbay & Kasierer as independent auditors for the fiscal year ending December 31, 2026, and until the next annual meeting. The board will determine the auditor’s remuneration on the audit committee’s recommendation. A total of 204,331,510 ordinary shares, approximately 80.9% of issued and outstanding ordinary shares as of the record date, were present or represented by proxy.
Cellebrite DI Ltd. (symbol: CLBT) is the issuer of record for a Form 4 filing submitted to the SEC. Van Buren Brandon reported acquisition or exercise transactions in this Form 4 filing.
Cellebrite DI Ltd. (CLBT) reported that director Brandon Van Buren received an equity compensation award in the form of 15,190 restricted share units (RSUs) on September 17, 2026. The RSUs will vest on September 17, 2027, with each RSU delivering one Ordinary Share upon settlement, increasing his directly held Ordinary Shares to 50,744.
Cellebrite DI Ltd. (symbol: CLBT) is the issuer of record for a Form 4 filing submitted to the SEC. Richardson Troy reported acquisition or exercise transactions in this Form 4 filing.
Cellebrite DI Ltd. (CLBT) reported that director Troy Richardson received a grant of 15,190 restricted share units (RSUs) on September 17, 2026. The RSUs will vest on September 17, 2027, with each RSU settling into one Ordinary Share. Following this award, Richardson directly holds 36,164 Ordinary Shares. The grant carries a stated price of $0.00 per share, indicating a compensation-related equity award rather than a market purchase.